Table 2.
Treatments and clinical outcomes of mild coronavirus disease 2019 patients with or without pneumonia development
| Variable | Pneumonia (n = 34) | No pneumonia (n = 93) | p value |
|---|---|---|---|
| Treatment | |||
| Lopinavir/ritonavir | 19 (55.9) | 7 (7.5) | < 0.001 |
| Hydroxychloroquine | 2 (5.9) | 1 (1.1) | 0.358 |
| Antibiotics | 14 (41.2) | 4 (4.3) | < 0.001 |
| Oxygen supplementation | 5 (14.7) | 0 | 0.001 |
| Mechanical ventilation | 0 | 0 | NA |
| ECMO | 0 | 0 | NA |
| Clinical outcome | |||
| Time to negative conversion | 23.6 ± 8.9 | 18.4 ± 8.5 | 0.003 |
| Negative conversion at 14 day | 3 (8.8) | 33 (35.5) | 0.006 |
| Negative conversion at 28 day | 24 (70.6) | 77 (82.8) | 0.207 |
| In-hospital death | 0 | 0 | NA |
Values are presented as number (%) or mean ± SD.
NA, not applicable; ECMO, extracorporeal membrane oxygenation.